BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 6816811)

  • 1. Synergistic activation by collagen and 15-hydroxy-9 alpha,11 alpha-peroxidoprosta-5,13-dienoic acid (PGH2) of phosphatidylinositol metabolism and arachidonic acid release in human platelets.
    Rittenhouse SE; Allen CL
    J Clin Invest; 1982 Dec; 70(6):1216-24. PubMed ID: 6816811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mobilization of arachidonic acid in collagen-stimulated human platelets.
    Vedelago HR; Mahadevappa VG
    Biochem J; 1988 Dec; 256(3):981-7. PubMed ID: 3146982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel arachidonic acid metabolites formed by prostaglandin H synthase.
    Hecker M; Ullrich V; Fischer C; Meese CO
    Eur J Biochem; 1987 Nov; 169(1):113-23. PubMed ID: 3119336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
    Gorman RR; Fitzpatrick FA; Miller OV
    Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243
    [No Abstract]   [Full Text] [Related]  

  • 5. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
    Brace LD; Venton DL; Le Breton GC
    Am J Physiol; 1985 Jul; 249(1 Pt 2):H1-7. PubMed ID: 3925795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of OKY 1581 on bronchoconstrictor responses to arachidonic acid and PGH2.
    Tilden SJ; Underwood DC; Cowen KH; Wegmann MJ; Graybar GB; Hyman AL; McNamara DB; Kadowitz PJ
    J Appl Physiol (1985); 1987 May; 62(5):2066-74. PubMed ID: 2954941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient concentrations and agonist potency of PGH2 in platelet activation by endogenous arachidonate.
    Hornberger W; Patscheke H
    Eicosanoids; 1989; 2(4):241-8. PubMed ID: 2517034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a bidirectional prostaglandin endoperoxide shunt between platelets and the bovine coronary artery.
    Mayeux PR; Kadowitz PJ; McNamara DB
    Biochim Biophys Acta; 1989 Mar; 1011(1):18-24. PubMed ID: 2493809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inhibition of arachidonic acid metabolism in human platelets by RHC 80267, a diacylglycerol lipase inhibitor.
    Oglesby TD; Gorman RR
    Biochim Biophys Acta; 1984 Apr; 793(2):269-77. PubMed ID: 6424715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of collagen-induced platelet activation by 5'-p-fluorosulfonylbenzoyl adenosine: evidence for an adenosine diphosphate requirement and synergistic influence of prostaglandin endoperoxides.
    Colman RW; Figures WR; Scearce LM; Strimpler AM; Zhou FX; Rao AK
    Blood; 1986 Aug; 68(2):565-70. PubMed ID: 3730618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R; Mezzasoma AM; Venditti G; Gresele P
    Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of prostaglandin biosynthesis by SQ 28,852, a 7-oxabicyclo[2.2.1]heptane analog.
    Harris DN; Phillips MB; Michel IM; Goldenberg HJ; Steinbacher TE; Ogletree ML; Hall SE
    Prostaglandins; 1986 Apr; 31(4):651-67. PubMed ID: 3088677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
    Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
    Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin endoperoxides promote calcium release from a platelet membrane fraction in vitro.
    Gerrard JM; Butler AM; Graff G; Stoddard SF; White JG
    Prostaglandins Med; 1978 Nov; 1(5):373-85. PubMed ID: 364508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
    Hornberger WB; Patscheke H
    Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets.
    Brace LD; Venton DL; Le Breton GC
    Am J Physiol; 1985 Jul; 249(1 Pt 2):H8-13. PubMed ID: 2409821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triene prostaglandins: prostaglandin D3 and icosapentaenoic acid as potential antithrombotic substances.
    Whitaker MO; Wyche A; Fitzpatrick F; Sprecher H; Needleman P
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5919-23. PubMed ID: 230492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin H2 directly lowers human platelet cAMP levels.
    Rybicki JP; Le Breton GC
    Thromb Res; 1983 Jun; 30(5):407-14. PubMed ID: 6310815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction by arachidonic acid of prostaglandin I2-induced cyclic AMP formation. Involvement of prostaglandins E2 and F2 alpha.
    Faili A; Randon J; Vargaftig BB; Hatmi M
    Biochem Pharmacol; 1993 May; 45(9):1815-20. PubMed ID: 8388209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.